SciELO - Scientific Electronic Library Online

vol.40 issue4Primary endocardial fibroelastosis: study of 11 casesAngiomatoid fibrous histiocytoma presenting metastasis: case report and literature review author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




Related links


Jornal Brasileiro de Patologia e Medicina Laboratorial

Print version ISSN 1676-2444On-line version ISSN 1678-4774


SALES, Alexandre de Oliveira; RODRIGUES, Sarah Jane de Paiva  and  BACCHI, Carlos E.. A comparative study between LSAB®+ and Herceptest® in the detection of HER-2/neu in breast carcinoma. J. Bras. Patol. Med. Lab. [online]. 2004, vol.40, n.4, pp.265-271. ISSN 1678-4774.

INTRODUCTION: The overexpression of human epidermal growth factor receptor (HER-2/neu) protein and the amplification of its gene are indicators of more aggressive behavior in breast cancer. The Food and Drug Administration (FDA) has approved HercepTest® with the goal of selecting patients to be elegible for treatment with the humanized murine monoclonal antibody anti-HER-2/neu (trastuzumab). AIMS: The aim of the present study was to compare the results of HER-2/neu expression using routine immunohistochemistry method LSAB®+ (Dakocytomation polyclonal antibody A0485) and HercepTest®. MATERIAL AND METHODS: 50 cases of breast carcinoma previously evaluated for HER-2/neu expression by routine immunohistochemistry using the LSAB+ method were included. These cases were also evaluated for HER-2/neu expression using HercepTest® for comparison. Results: 34 cases of breast carcinoma were negative for HER-2/neu expression by the two methods, with score 0 by HercepTest®. In 12 and 22 cases, respectively, score 1+ and 0 were observed by the LSAB®+ method. In eight cases, score 2+ was present by both methods. Score 3+ was found in eight cases also by both methods. DISCUSSION: The most common method used in routine clinical practice to determine HER-2/neu status is immunohistochemistry. Variability of HER-2/neu results can be caused by a number of variables including time of fixation, methods of epitope retrieval and type of primary antibodies used. CONCLUSION: The conclusion of the present study was that LSAB®+ and HercepTest® revealed equivalent results for HER-2/neu expression in breast carcinoma.

Keywords : Carcinoma; Breast; C-erbB-2; HER-2/neu; Overexpression; Immunohistochemistry.

        · abstract in Portuguese     · text in Portuguese     · Portuguese ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License